TDOC

TELADOC HEALTH INC

Healthcare | Small Cap

-$0.20

EPS Forecast

$580.8

Revenue Forecast

The company already released most recent quarter's earnings. We will publish our AI's next quarter's forecast around 2026-12-31

Teladoc Health Q3 2026: Two Segments, One Clear Boundary on Earnings

TDOC reports third-quarter results with revenue near the high end of guidance, EPS at a modest negative print, and a mixed signal from its two business lines as the company navigates a competitive telehealth landscape.

Overview

Teladoc Health, Inc., trading on the NYSE under the ticker TDOC, disclosed its third quarter 2026 results on October 28, 2026. For the three months ended September 30, 2026, the company reported revenue of $605.1 million, a 3% year-over-year decline. Net loss was $26.9 million, or EPS of $0.15 per share. On an adjusted basis, Teladoc posted EBITDA of $79.4 million, up 14% versus the prior year.

Management framed the quarter as a tale of two segments: Integrated Care and BetterHelp. Integrated Care produced revenue of $398.5 million, up 2% year over year, with an adjusted EBITDA margin of 18.8%. BetterHelp delivered $206.6 million in revenue, down 13% year over year, with a thinner EBITDA margin of 2.2%.

The company noted that its results sit near the upper end of its consolidated revenue guidance and above its range for consolidated adjusted EBITDA. In market terms, this translates into a subtle beat on the revenue side relative to expectations but with the ongoing challenge of profitability margins, especially in the consumer-facing BetterHelp unit.

Key Highlights

  • Three months ended Sept. 30, 2026: Revenue $605.1 million, down 3% year over year; EPS - $0.15 per share; Net loss $26.9 million.
  • Adjusted EBITDA for the quarter: $79.4 million, up 14% year over year.
  • Integrated Care revenue: $398.5 million (+2% YoY); Adjusted EBITDA margin: 18.8%.
  • BetterHelp revenue: $206.6 million (−13% YoY); EBITDA margin: 2.2%.
  • Executive commentary emphasizes ongoing innovation (e.g., Teladoc One) and capacity expansion alongside efforts to scale AI-enabled solutions.

What the results imply for TDOC and its peers

The quarterly narrative is not a single plot but a two-act play. In Act I, the Integrated Care business remains the anchor, delivering revenue that barely edges up while preserving a robust EBITDA margin. That margin suggests discipline around cost and a focus on the more predictable, enterprise-oriented portion of the business where reimbursement and utilization patterns can be steadier.

Act II centers on BetterHelp, where topline softness and a narrow margin profile underscore the volatility one might expect from a consumer-directed, insurance-revenue–sensitive unit. The disparity between the two segments underscores a theme common in healthcare platforms: the core, more predictable business is not immune to macro pressure, while consumer-facing services can swing with insurance dynamics and marketing intensity.

From a valuation and investor-relations lens, the company’s commentary that Q3 results sit near the high end of its revenue guidance while EBITDA prints above the guidance range may temper expectations around near-term profitability but signals a willingness to lean into margin expansion where the business mix allows. The presence of notable product initiatives—such as hybrid care and AI-enabled solutions—could serve as catalysts for longer-term margin recovery if adoption accelerates and payer mixes shift favorably.

In terms of market discipline, the EPS outcome—-0.15 for the quarter—will be weighed against the EPS consensus by analysts and investors, who will parse whether Teladoc’s path to sustainable profitability hinges on squeezing more efficiency from BetterHelp or pushing more value from Integrated Care through pricing, utilization gains, or productization. The implied narrative is that the company is tightening its operating model, but the road to durable earnings growth remains uneven and highly contingent on reimbursement dynamics and consumer demand.

Financial snapshot

All figures are in thousands, unless noted otherwise, and unaudited. The press release highlights the following for the quarter:

  • Revenue: $605,100
  • Net loss: $26,900
  • EPS: $(0.15)
  • Adjusted EBITDA: $79,400
  • Integrated Care revenue: $398,500; Adjusted EBITDA margin: 18.8%
  • BetterHelp revenue: $206,600; EBITDA margin: 2.2%

Notes accompany the release that these figures reflect Three Months Ended September 30, 2026, with the company continuing to present “In thousands, except per share data” and to classify results as unaudited for the quarter. The Nine Months Ended line items appear in the same data set, but the quarter-to-quarter comparison emphasizes the shifts within the two main segments rather than a single consolidated narrative.

Outlook and guidance

The management tone emphasizes a continued focus on revenue forecast discipline and progress toward improved earnings quality, even as the near-term EPS remains pressured by mix and investment. The quarterly commentary frames the results as consistent with a multi-year path—where adoption of new capabilities (like Teladoc One) and expansion of hybrid care approaches could gradually lift margins and drive more stable growth across Integrated Care and the broader platform.

Analysts will scrutinize whether the earnings surprise potential lies in the ability of the telehealth network to convert higher utilization and payer acceptance into EBITDA expansion, rather than a straightforward top-line acceleration. The EPS consensus will be tested against the realized loss per share, while the company’s next quarterly update will be the first real signal of whether the current strategic investments begin to translate into tangible profitability gains.

Management commentary

"We delivered third-quarter results near the upper end of our guidance range for consolidated revenue and above our range for consolidated adjusted EBITDA, reflecting solid execution across our two segments," said Chuck Divita, Chief Executive Officer of Teladoc Health. "Within Integrated Care, we continue to advance our innovation agenda, including the implementation of Teladoc One with our early launch partners, while expanding capacity and AI-enabled solutions. In BetterHelp, insurance revenue exceeded expectations, and we are making progress expanding provider capacity and scaling access to covered services. There is more work ahead, but we remain focused on disciplined execution against our strategic priorities."

Bottom line

Teladoc’s Q3 narrative reinforces a familiar theme for multi-segment health tech platforms: a steady, highly marginable core juxtaposed with a consumer-facing volume play that’s more volatile. The stock’s immediate reaction will hinge on how investors price the trajectory of BetterHelp’s margins and how convincingly the company can translate investments in AI and platform integration into real, sustainable EBITDA gains. In the meantime, the revenue forecast discipline and the divergence between the two business lines will keep TDOC—and its sector peers—transparent about the trade-offs between growth and profitability.

Source: Teladoc Health, Inc. press release and accompanying materials, October 28, 2026. For reference, the company trades under ticker TDOC on the NYSE.